The effect of sodium‐glucose cotransporter 2 inhibitors and glucagon‐like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes
| Autor: | Jacob Groenendyk, Evgenia Gourgari, Amit K. Dey, Nehal N. Mehta |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Cvd risk
Reviews Type 2 diabetes Disease Review 030204 cardiovascular system & hematology Pharmacology Global Health 03 medical and health sciences 0302 clinical medicine Glucagon-Like Peptide 1 Diabetes mellitus medicine Secondary Prevention Humans Hypoglycemic Agents In patient 030212 general & internal medicine cardiovascular diseases Sodium-Glucose Transporter 2 Inhibitors diabetes business.industry Incidence Glucagon-like Peptide-1 Agonists General Medicine medicine.disease Prognosis 3. Good health SGLT‐2 inhibitors GLP‐1 agonists Survival Rate Increased risk Diabetes Mellitus Type 2 Cardiovascular Diseases Sodium/Glucose Cotransporter 2 Cardiology and Cardiovascular Medicine business |
| Zdroj: | Clinical Cardiology |
| ISSN: | 1932-8737 0160-9289 |
| Popis: | Patients with type 2 diabetes have a significantly increased risk of cardiovascular disease (CVD) compared to the general population-with CVD accounting for two out of every three deaths in patients with diabetes. In 2008, the FDA suggested that CVD risk should be evaluated for any new antidiabetic therapy, leading to a multitude of large CVD outcome trials to assess CVD risk from these medications. Interestingly, several of these outcome trials with new novel antidiabetic therapies have demonstrated a clear and definite CVD advantage at mid-term follow up in high-risk patients with T2DM. In this review, we discuss two relatively new classes of diabetic drugs, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists, and their efficacy in improving cardiovascular outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text